Yuval Cohen's most recent trade in Corbus Pharmaceuticals Holdings Inc was a trade of 7,134 Common Stock, par value $0.0001 per share done at an average price of $8.8 . Disclosure was reported to the exchange on Feb. 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.76 per share. | 14 Feb 2025 | 7,134 | 138,187 (0%) | 0% | 8.8 | 62,465 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 228,800 | 228,800 | - | - | Stock options (right to buy) | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 68,100 | 145,321 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.10 per share. | 14 Jun 2024 | 16,830 | 101,230 (0%) | 0% | 14.1 | 237,303 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.17 per share. | 14 Jun 2024 | 16,830 | 84,400 (0%) | 0% | 50.2 | 844,297 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 16,830 | 32,827 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 12,487 | 96,887 (0%) | 0% | 4.3 | 53,195 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.17 per share. | 14 Jun 2024 | 12,487 | 84,400 (0%) | 0% | 50.2 | 626,425 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 12,487 | 53,831 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 11,667 | 96,067 (0%) | 0% | 30 | 350,010 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 14 Jun 2024 | 11,667 | 84,400 (0%) | 0% | 42.2 | 492,779 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 11,667 | 0 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 14 Jun 2024 | 9,333 | 93,733 (0%) | 0% | 30 | 279,990 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.02 per share. | 14 Jun 2024 | 9,333 | 84,400 (0%) | 0% | 46.0 | 429,507 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 9,333 | 11,667 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 14 Jun 2024 | 7,179 | 77,221 (0%) | 0% | 42.2 | 303,219 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 2,322 | 86,722 (0%) | 0% | 4.3 | 9,892 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 14 Jun 2024 | 2,322 | 84,400 (0%) | 0% | 42.2 | 98,074 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 2,322 | 49,739 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.24 per share. | 14 Jun 2024 | 1,770 | 84,400 (0%) | 0% | 42.2 | 74,759 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.26 per share. | 14 Jun 2024 | 1,770 | 86,170 (0%) | 0% | 4.3 | 7,540 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.02 per share. | 14 Jun 2024 | 1,770 | 84,400 (0%) | 0% | 46.0 | 81,456 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.10 per share. | 14 Jun 2024 | 1,770 | 86,170 (0%) | 0% | 14.1 | 24,957 | Common Stock, par value $0.0001 per share |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,770 | 52,061 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,770 | 31,057 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 73,947 | 84,400 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 73,947 | 73,947 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals Hol... | Cohen Yuval | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 7,179 | 0 | - | - | Options to purchase common stock | |
| Corbus Pharmaceuticals Hol... | Cohen Yuval | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.97 per share. | 26 Jan 2024 | 7,179 | 7,179 (0%) | 0% | 5.0 | 35,680 | Common Stock |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.26 per share. | 10 Aug 2022 | 3,800 | 98,230 (0%) | 0% | 0.3 | 1,003 | Common Stock |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.25 per share. | 16 May 2022 | 10,500 | 94,430 (0%) | 0% | 0.3 | 2,625 | Common Stock |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.37 per share. | 09 Mar 2022 | 8,600 | 83,930 (0%) | 0% | 0.4 | 3,182 | Common Stock |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2022 | 1,989,546 | 1,949,546 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 1,489,700 | 1,489,700 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 956,500 | 956,500 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 956,500 | 956,500 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals Hol... | Yuval Cohen | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.21 per share. | 11 Nov 2020 | 4,240 | 75,330 (0%) | 0% | 1.2 | 5,126 | Common Stock |